Decker William K, Xing Dongxia, Shpall Elizabeth J
Department of Blood and Marrow Transplantation, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Biol Blood Marrow Transplant. 2006 Feb;12(2):113-25. doi: 10.1016/j.bbmt.2005.09.003.
It has long been promised that dendritic cell immunotherapy would revolutionize the treatment of neoplastic disease. Now, more than 10 years since the publication of the first clinical data, a firmer understanding of immunology and dendritic cell biology is beginning to produce interesting clinical results. This article reviews the clinical trials that established many of the concepts with which today's investigators are achieving improved results, discusses issues in dendritic cell immunotherapy that are currently unresolved, and offers a perspective on the strategies that the authors believe will be important for the design of future vaccine trials, including the use of Toll-like receptor agonists as maturation agents, the accessory use of the plasmacytoid dendritic cell subset, and the maximization of T-cell help.
长期以来，人们一直期待树突状细胞免疫疗法能彻底改变肿瘤疾病的治疗方式。如今，自首批临床数据发表已过去十多年，对免疫学和树突状细胞生物学更深入的理解正开始产生有趣的临床结果。本文回顾了确立诸多概念的临床试验，如今的研究者正是凭借这些概念取得了更好的成果，讨论了树突状细胞免疫疗法中目前尚未解决的问题，并就作者认为对未来疫苗试验设计至关重要的策略提供了一种观点，包括使用Toll样受体激动剂作为成熟剂、辅助使用浆细胞样树突状细胞亚群以及最大化T细胞辅助作用。
